First, here’s a bit of good research news that involves The James:
(Reuters) – A closely watched leukemia drug developed by Johnson & Johnson and Pharmacyclics Inc maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow-up data from a midstage study being presented at a major medical meeting.
The oral drug, ibrutinib, last month won U.S. approval to treat a rare and aggressive form of non-Hodgkin lymphoma known as mantle cell lymphoma. It is awaiting a Food and Drug Administration decision on treating chronic lymphocytic leukemia (CLL), a slowly progressing form of blood cancer that primarily affects people aged 65 and older.
“With extended follow-up the remissions with ibrutinib appear to be continuing and the safety of this long-term is being maintained,” said Byrd, professor of internal medicine and director of hematology at the Ohio State University Comprehensive Cancer Center in Columbus.
This is a pretty big deal. The development of an effective cancer chemotherapy with significantly reduced toxic side effects is approaching Holy Grail status.
Now, moving on to cancer prevention in regards to kidney cancer, here’s a tip from The James; drink tea in the morning. On a personal note, our neighbor, and one of our best friends passed away from kidney cancer a year and a half ago, so this is a pretty touchy subject with me. Drink your morning tea!!